← Back to Search

Peptide

RLS-0071 for COPD

Phase 2
Recruiting
Research Sponsored by ReAlta Life Sciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Hospitalized participants with a prior diagnosis of COPD including spirometry within the prior year documenting a postbronchodilator FEV1/FVC ≤ 0.7 and an FEV1
≤ 80%, and a clinician identified admitting diagnosis of AECOPD: acute increase in dyspnea, sputum volume or purulence - without other attributable cause.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is studying a new treatment called RLS-0071 for adults with moderate exacerbations of COPD, which is a serious lung condition that can cause hospitalization and even death. Exacerb

Who is the study for?
This trial is for adults with moderate COPD flare-ups, who've smoked at least the equivalent of a pack a day for 10 years. They must have been diagnosed with COPD previously, shown by specific lung function tests within the last year and be hospitalized due to their current flare-up.
What is being tested?
The study is testing RLS-0071, a new peptide treatment for COPD exacerbations. Participants will either receive RLS-0071 or a placebo to assess the safety and how well it works in improving symptoms compared to not receiving the active drug.
What are the potential side effects?
Possible side effects are not detailed but typically include reactions where the drug is administered, potential allergic responses, general discomforts like headaches or nausea, and any other unexpected changes in health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have COPD, confirmed by a lung function test in the last year.
Select...
I have been diagnosed with a severe COPD flare-up without any other known cause.
Select...
I have had a moderate worsening of my COPD.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RLS-0071Experimental Treatment1 Intervention
Doses of RLS-0071, will be administered Q8H, three times a day, for at least 3 days and up to 5 days
Group II: PlaceboPlacebo Group1 Intervention
Doses of Placebo for RLS-0071, will be administered Q8H, three times a day, for at least 3 days and up to 5 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RLS-0071
2021
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

ReAlta Life Sciences, Inc.Lead Sponsor
5 Previous Clinical Trials
194 Total Patients Enrolled
~7 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top